Signaturefd LLC Acquires 2,541 Shares of Galapagos NV (NASDAQ:GLPG)

Signaturefd LLC increased its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 65.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,413 shares of the biotechnology company’s stock after buying an additional 2,541 shares during the quarter. Signaturefd LLC’s holdings in Galapagos were worth $185,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Headlands Technologies LLC lifted its stake in Galapagos by 949.3% in the 1st quarter. Headlands Technologies LLC now owns 787 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 712 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 736 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Galapagos by 21.6% in the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after acquiring an additional 814 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Galapagos by 783.6% during the 1st quarter. BNP Paribas Financial Markets now owns 5,328 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 4,725 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in Galapagos during the 2nd quarter worth $284,000. 32.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GLPG shares. Raymond James cut Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a research report on Monday, September 9th. Finally, Leerink Partners initiated coverage on shares of Galapagos in a research note on Monday, September 9th. They set a “market perform” rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $31.00.

Galapagos Stock Performance

Galapagos stock opened at $28.95 on Monday. The firm has a 50 day moving average price of $28.97 and a two-hundred day moving average price of $27.78. Galapagos NV has a 52-week low of $24.16 and a 52-week high of $42.46.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.